Ebola and marburg hemorrhagic fever

Clinics in Laboratory Medicine

Volumn 30, Issue 1, 2010, Pages 161-177

  Hartman, Amy L ^a,b   Towner, Jonathan S ^c   Nichol, Stuart T ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Ebola; Filovirus; Hemorrhagic fever; Marburg

Indexed keywords

ACTIVATED PROTEIN C; ADENOSYLHOMOCYSTEINASE INHIBITOR; ANTICOAGULANT AGENT; EBOLA VACCINE; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; SMALL INTERFERING RNA;

CLINICAL FEATURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; HISTOPATHOLOGY; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INFECTION PREVENTION; LABORATORY DIAGNOSIS; MARBURG HEMORRHAGIC FEVER; MARBURG VIRUS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYMPTOM; TREATMENT OUTCOME; VACCINATION; VIRUS ISOLATION; VIRUS PATHOGENESIS;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; FILOVIRIDAE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MARBURG VIRUS DISEASE; PHYLOGENY; VIRAL VACCINES;

EID: 77953351485     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2009.12.001     Document Type: Review

References (62)

1. Regnery R.L., Johnson K.M., Kiley M.P. Virion nucleic acid of Ebola virus. J Virol 1980, 36(2):465-469.
2. Suzuki Y., Gojobori T. The origin and evolution of Ebola and Marburg viruses. Mol Biol Evol 1997, 14(8):800-806.
3. Towner J.S., Sealy T.K., Khristova M.L., et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008, 4(11):e1000212.
4. Formenty P., Hatz C., Le Guenno B., et al. Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. J Infect Dis 1999, 179(Suppl 1):S48-S53.
5. World Health Organization Ebola Reston in pigs and humans in the Philippines: update Available at:, Accessed April 27, 2009. http://www.who.int/csr/don/2009_03_31/en/index.html.
6. Centers for Disease Control and Prevention Marburg hemorrhagic fever, imported case-United States Available at:, Accessed June 20, 2009. http://www.cdc.gov/ncidod/dvrd/spb/outbreaks/index.htm.
7. World Health Organization Epidemic and pandemic alert and response (EPR): case of Marburg haemorrhagic fever imported into the Netherlands from Uganda Available at:, Accessed June 20, 2009. http://www.who.int/csr/don/2008_07_10/en/index.html.
8. US Department of Health and Human Services Biosafety in microbiological and biomedical laboratories 2007, U.S. Government Printing Office, Washington, DC. 5th edition.
9. Sanchez A., Geisbert T.W., Feldmann H. Filoviridae: Marburg and Ebola viruses. Fields virology 2007, 1409-1448. Lippincott-Raven, Philadelphia. 5th edition. B.M. Knipe, P.M. Howley, D.E. Griffen (Eds.).
10. Colebunders R., Tshomba A., Van Kerkhove M.D., et al. Marburg hemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of illness, and treatment. J Infect Dis 2007, 196(Suppl 2):S148-S153.
11. Ksiazek T.G., Rollin P.E., Williams A.J., et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999, 179(Suppl 1):S177-S187.
12. Towner J.S., Rollin P.E., Bausch D.G., et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 2004, 78(8):4330-4341.
13. Bwaka M.A., Bonnet M.J., Calain P., et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 1999, 179(Suppl 1):S1-S7.
14. Zaki S.R., Goldsmith C.S. Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol 1999, 235:97-116.
15. Smith D.H., Johnson B.K., Isaacson M., et al. Marburg-virus disease in Kenya. Lancet 1982, 1(8276):816-820.
16. Emond R.T., Evans B., Bowen E.T., et al. A case of Ebola virus infection. Br Med J 1977, 2(6086):541-544.
17. Rowe A.K., Bertolli J., Khan A.S., et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999, 179(Suppl 1):S28-S35.
18. Bray M., Geisbert T.W. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 2005, 37(8):1560-1566.
19. Geisbert T.W., Hensley L.E., Larsen T., et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003, 163(6):2347-2370.
20. Geisbert T.W., Young H.A., Jahrling P.B., et al. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003, 188(11):1618-1629.
21. Simmons G., Reeves J.D., Grogan C.C., et al. DC-SIGN and DC-SIGNR bind Ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 2003, 305(1):115-123.
22. Baize S., Leroy E.M., Georges-Courbot M.C., et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999, 5(4):423-426.
23. Gupta M., Mahanty S., Ahmed R., et al. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with Ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology 2001, 284(1):20-25.
24. Bosio C.M., Aman M.J., Grogan C., et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003, 188(11):1630-1638.
25. Mahanty S., Hutchinson K., Agarwal S., et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003, 170(6):2797-2801.
26. Geisbert T.W., Hensley L.E., Gibb T.R., et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000, 80(2):171-186.
27. Harcourt B.H., Sanchez A., Offermann M.K. Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J Virol 1999, 73(4):3491-3496.
28. Hartman A.L., Bird B.H., Towner J.S., et al. Inhibition of IRF-3 activation by VP35 is critical for the high virulence of Ebola virus. J Virol 2008, 82(6):2699-2704.
29. Hartman A.L., Towner J.S., Nichol S.T. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 2004, 328(2):177-184.
30. Reid S.P., Leung L.W., Hartman A.L., et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 2006, 80(11):5156-5167.
31. Ruf W. Emerging roles of tissue factor in viral hemorrhagic fever. Trends Immunol 2004, 25(9):461-464.
32. Towner J.S., Khristova M.L., Sealy T.K., et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol 2006, 80(13):6497-6516.
33. Towner J.S., Sealy T.K., Ksiazek T.G., et al. High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. J Infect Dis 2007, 196(Suppl 2):S205-S212.
34. Centers for Disease Control and Prevention Interim guidance for managing patients with suspected viral hemorrhagic fever in U.S. Hospitals Available at:, Accessed June 5, 2009. http://www.cdc.gov/ncidod/dhqp/bp_vhf_interimGuidance.html.
35. Bausch D.G., Towner J.S., Dowell S.F., et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007, 196(Suppl 2):S142-S147.
36. Peters C.J., Jahrling P.B., Khan A.S. Patients infected with high-hazard viruses: scientific basis for infection control. Arch Virol Suppl 1996, 11:141-168.
37. Francesconi P., Yoti Z., Declich S., et al. Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. Emerg Infect Dis 2003, 9(11):1430-1437.
38. Baron R.C., McCormick J.B., Zubeir O.A. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ 1983, 61(6):997-1003.
39. Kerstiens B., Matthys F. Interventions to control virus transmission during an outbreak of Ebola hemorrhagic fever: experience from Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999, 179(Suppl 1):S263-S267.
40. Georges A.J., Leroy E.M., Renaut A.A., et al. Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: epidemiologic and health control issues. J Infect Dis 1999, 179(Suppl 1):S65-S75.
41. World Health Organization Marburg hemmorrhagic fever in Angola-Update 26 Available at:, Accessed June 7, 2009. http://www.who.int/csr/don/2005_11_07a/en/index.html.
42. Bausch D.G., Sprecher A.G., Jeffs B., et al. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res 2008, 78(1):150-161.
43. Takada A., Ebihara H., Jones S., et al. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 2007, 25(6):993-999.
44. Mupapa K., Massamba M., Kibadi K., et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999, 179(Suppl 1):S18-S23.
45. Jahrling P.B., Geisbert J., Swearengen J.R., et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 1996, 11:135-140.
46. Jahrling P.B., Geisbert J.B., Swearengen J.R., et al. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 2007, 196(Suppl 2):S400-S403.
47. Oswald W.B., Geisbert T.W., Davis K.J., et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 2007, 3(1):e9.
48. Huggins J.W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989, 11(Suppl 4):S750-S761.
49. Jahrling P.B., Geisbert T.W., Geisbert J.B., et al. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis 1999, 179(Suppl 1):S224-S234.
50. Geisbert T.W., Hensley L.E., Kagan E., et al. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 2006, 193(12):1650-1657.
51. Geisbert T.W., Hensley L.E., Jahrling P.B., et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003, 362(9400):1953-1958.
52. Bray M., Raymond J.L., Geisbert T., et al. 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res 2002, 55(1):151-159.
53. Bray M., Driscoll J., Huggins J.W. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res 2000, 45(2):135-147.
54. Hensley L.E., Stevens E.L., Yan S.B., et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007, 196(Suppl 2):S390-S399.
55. Feldmann H., Jones S.M., Daddario-DiCaprio K.M., et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007, 3(1):e2.
56. Reed D.S., Mohamadzadeh M. Status and challenges of filovirus vaccines. Vaccine 2007, 25(11):1923-1934.
57. Geisbert T.W., Pushko P., Anderson K., et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002, 8(5):503-507.
58. Ignatyev G.M., Agafonov A.P., Streltsova M.A., et al. Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys. J Biotechnol 1996, 44(1-3):111-118.
59. Swenson D.L., Warfield K.L., Kuehl K., et al. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol 2004, 40(1):27-31.
60. Warfield K.L., Swenson D.L., Olinger G.G., et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007, 196(Suppl 2):S430-S437.
61. Swenson D.L., Warfield K.L., Negley D.L., et al. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005, 23(23):3033-3042.
62. Swenson D.L., Warfield K.L., Larsen T., et al. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines 2008, 7(4):417-429.